Skip to content
AnalystLens

CARPENTER TECHNOLOGY CORP 8-K Report, Financial Results (Oct 22, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 22, 2026
Period End
October 22, 2026
Security
CRS
In the record · 2016–202610-K1110-Q338-K141

CRS filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Apr ’17Apr ’17
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’21Oct ’21
  4. Material agreement8-K · Nov ’25Nov ’25

Summary

Summary of the 8-K filed October 22, 2026. Cited figures are marked; the original filing is the authoritative source.

Carpenter Technology Corporation (CRS) has reported its first quarter fiscal year 2027 results, showcasing significant year-over-year growth in operating income and an expansion of operating margins, particularly within its Specialty Alloys Operations (SAO) segment.

The company highlights strengthening demand across key end-use markets, with notable acceleration in Aerospace and Defense, driven by increasing production rates and robust MRO activity. Pricing environment remains favorable, with opportunities for further upside in long-term agreements (LTAs). Financially, CRS delivered strong operating income growth of 28%a year-over-year, accompanied by a notable increase in adjusted operating margin.

While net sales saw a sequential dip, year-over-year sales growth was positive. The company also repurchased a substantial amount of stock and authorized a new $1.0 billionb share repurchase program, underscoring a commitment to returning capital to shareholders, alongside a consistent quarterly dividend. Looking ahead, Carpenter Technology anticipates continued profit growth, margin expansion, and accelerating demand throughout fiscal year 2027, projecting free cash flow between $400 million and $430 million.

Key Highlights

  1. Q1 FY27 operating income increased by 28% year-over-year to $196.4 million, demonstrating strong performance.
  2. SAO segment reported a 27% year-over-year increase in operating income to $216.3 million, with adjusted operating margins at a strong 37.7%.
  3. Demand in the Aerospace and Defense sector is accelerating, with bookings up 23% sequentially and 49% year-over-year.
  4. The company repurchased $133.9 million of stock in the quarter and announced a new $1.0 billion share repurchase authorization.
  5. CRS anticipates generating between $400 million and $430 million in free cash flow for fiscal year 2027.
  6. The brownfield capacity expansion project remains on schedule and on budget, expected to come online in early FY28.

Frequently Asked Questions

  1. What was the primary driver of the strong year-over-year operating income growth?

    The primary driver was strong execution and an improving demand and pricing environment, especially in the Aerospace and Defense end-use market, leading to increased sales and expanded operating margins within the Specialty Alloys Operations (SAO) segment.

  2. How is the company addressing shareholder returns?

    Carpenter Technology is returning capital to shareholders through a consistent quarterly cash dividend and significant share repurchases. In the first quarter of FY27, the company repurchased $133.9 million of stock, completed a prior authorization, and authorized a new $1.0 billion share repurchase program.

  3. What is the outlook for free cash flow and future growth?

    The company anticipates generating $400 million to $430 million in free cash flow for fiscal year 2027. Looking further ahead, Carpenter Technology has set a FY29 operating income target that represents a 20% to 23% earnings CAGR over three years, with market dynamics expected to continue strengthening beyond that period.

  4. How are segment performances trending, particularly SAO and PEP?

    The SAO segment is experiencing accelerated demand and strong operating income growth with expanding margins, driven by Aerospace and Defense. The PEP (Performance Engineered Products) segment saw a slight year-over-year decrease in net sales, primarily due to lower sales in the Medical end-use market, though operating income was in line with expectations.